Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
2004 1
2005 1
2007 1
2009 5
2012 1
2013 2
2014 6
2015 5
2016 5
2017 3
2018 4
2019 5
2020 9
2021 5
2023 5
2024 4
2025 10
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Bakris GL, et al. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. N Engl J Med. 2020. PMID: 33264825 Free article. Clinical Trial.
Eligible patients had a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of 30 to less than 300, an estimated glomerular filtration rate (eGFR) of 25 to less than 60 ml per minute per 1.73 m(2) of body-surface area, …
Eligible patients had a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of 30 to …
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Pitt B, et al. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449181 Clinical Trial.
Eligible patients had a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of 30 to less than 300 and an estimated glomerular filtration rate (eGFR) of 25 to 90 ml per minute per 1.73 m(2) of body-surface area (stage …
Eligible patients had a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of 30 to …
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
Walsh M, Merkel PA, Peh CA, Szpirt WM, Puéchal X, Fujimoto S, Hawley CM, Khalidi N, Floßmann O, Wald R, Girard LP, Levin A, Gregorini G, Harper L, Clark WF, Pagnoux C, Specks U, Smyth L, Tesar V, Ito-Ihara T, de Zoysa JR, Szczeklik W, Flores-Suárez LF, Carette S, Guillevin L, Pusey CD, Casian AL, Brezina B, Mazzetti A, McAlear CA, Broadhurst E, Reidlinger D, Mehta S, Ives N, Jayne DRW; PEXIVAS Investigators. Walsh M, et al. N Engl J Med. 2020 Feb 13;382(7):622-631. doi: 10.1056/NEJMoa1803537. N Engl J Med. 2020. PMID: 32053298 Free PMC article. Clinical Trial.
METHODS: We conducted a randomized trial with a 2-by-2 factorial design to evaluate the use of plasma exchange and two regimens of oral glucocorticoids in patients with severe ANCA-associated vasculitis (defined by an estimated glomerular filtration rate of <50 ml per minute p …
METHODS: We conducted a randomized trial with a 2-by-2 factorial design to evaluate the use of plasma exchange and two regimens of oral gluc …
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.
Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, Michel PA, Mihout F, Dussol B, Matignon M, Mousson C, Simon T, Ronco P; GEMRITUX Study Group. Dahan K, et al. J Am Soc Nephrol. 2017 Jan;28(1):348-358. doi: 10.1681/ASN.2016040449. Epub 2016 Jun 27. J Am Soc Nephrol. 2017. PMID: 27352623 Free PMC article. Clinical Trial.
Patients with biopsy-proven PMN and nephrotic syndrome after 6 months of nonimmunosuppressive antiproteinuric treatment (NIAT) were randomly assigned to 6-month therapy with NIAT and 375 mg/m(2) intravenous rituximab on days 1 and 8 (n=37) or NIAT alone (n=38). Median time …
Patients with biopsy-proven PMN and nephrotic syndrome after 6 months of nonimmunosuppressive antiproteinuric treatment (NIAT) were randomly …
Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan.
Cortazar FB, Niles JL, Jayne DRW, Merkel PA, Bruchfeld A, Yue H, Schall TJ, Bekker P; ADVOCATE Study Group. Cortazar FB, et al. Kidney Int Rep. 2023 Feb 3;8(4):860-870. doi: 10.1016/j.ekir.2023.01.039. eCollection 2023 Apr. Kidney Int Rep. 2023. PMID: 37069984 Free PMC article.
INTRODUCTION: In the 330-patient ADVOCATE trial of avacopan for the treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, in which 81% of patients had renal involvement, estimated glomerular filtration rate (eGFR) increased on average 7.3 ml/min per 1 …
INTRODUCTION: In the 330-patient ADVOCATE trial of avacopan for the treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated v …
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, Tuttle KR, Ruilope LM, Rossing P, Toto R, Anker SD, Liu ZH, Joseph A, Ahlers C, Brinker M, Lawatscheck R, Bakris G; FIDELIO-DKD and FIGARO-DKD Investigators. Sarafidis P, et al. Clin J Am Soc Nephrol. 2023 May 1;18(5):602-612. doi: 10.2215/CJN.0000000000000149. Epub 2023 Apr 7. Clin J Am Soc Nephrol. 2023. PMID: 36927680 Free PMC article. Clinical Trial.
METHODS: This FIDELITY subgroup analysis investigated the effects of finerenone in participants with stage 4 CKD (eGFR <30 ml/min per 1.73 m 2 ). Efficacy outcomes included a cardiovascular composite (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke …
METHODS: This FIDELITY subgroup analysis investigated the effects of finerenone in participants with stage 4 CKD (eGFR <30 ml/min per 1.7 …
Clinical and Prognostic Factors in Patients with IgG4-Related Kidney Disease.
Chaba A, Devresse A, Audard V, Boffa JJ, Karras A, Cartery C, Deltombe C, Chemouny J, Contamin C, Courivaud C, Duquennoy S, Garcia H, Joly D, Goumri N, Hanouna G, Halimi JM, Plaisier E, Hamidou M, Landron C, Launay D, Lebas C, Legendre M, Masseau A, Mathian A, Mercadal L, Morel N, Mutinelli-Szymanski P, Palat S, Pennaforte JL, Peraldi MN, Pozdzik A, Schleinitz N, Thaunat O, Titeca-Beauport D, Mussini C, Touati S, Prinz E, Faller AL, Richter S, Vilaine E, Ferlicot S, Von-Kotze C, Belliere J, Olagne J, Mesbah R, Snanoudj R, Nouvier M, Ebbo M, Zaidan M. Chaba A, et al. Clin J Am Soc Nephrol. 2023 Aug 1;18(8):1031-1040. doi: 10.2215/CJN.0000000000000193. Epub 2023 Jun 7. Clin J Am Soc Nephrol. 2023. PMID: 37283461 Free PMC article.
Logistic regression was performed to identify the possible factors related to an eGFR 30 ml/min per 1.73 m 2 at the last follow-up. Cox proportional hazards model was performed to assess the factors associated with the risk of relapse. ...At the last follow-up, the eGFR w …
Logistic regression was performed to identify the possible factors related to an eGFR 30 ml/min per 1.73 m 2 at the last follow-up. …
Treatment With Avacopan in ANCA-Associated Vasculitis With Kidney Involvement.
Geetha D, Cortazar FB, Bruchfeld A, Kronbichler A, Karras A, Nakhoul GN, Merkel PA, Bray S, Bozeman AM, Jayne DRW; ADVOCATE Study Group. Geetha D, et al. Kidney Int Rep. 2025 Jun 2;10(8):2751-2765. doi: 10.1016/j.ekir.2025.05.041. eCollection 2025 Aug. Kidney Int Rep. 2025. PMID: 40814647 Free PMC article.
Changes in estimated glomerular filtration rate (eGFR) were analyzed overall and stratified by baseline eGFR categories ( 90, 60-89, 45-59, 30-44, and 15-29 ml/min per 1.73 m(2)). Additional outcomes were changes in albuminuria and hematuria, glucocorticoid (GC) use, gluc …
Changes in estimated glomerular filtration rate (eGFR) were analyzed overall and stratified by baseline eGFR categories ( 90, 60-89, 45-59, …
Nitrogen accountancy in space agriculture.
Yates K, Berliner AJ, Makrygiorgos G, Kaiyom F, McNulty MJ, Khan I, Kusuma P, Kinlaw C, Miron D, Legg C, Wilson J, Bugbee B, Mesbah A, Arkin AP, Nandi S, McDonald KA. Yates K, et al. NPJ Microgravity. 2024 Sep 28;10(1):90. doi: 10.1038/s41526-024-00428-x. NPJ Microgravity. 2024. PMID: 39341860 Free PMC article.
Histologic Features Associated with Kidney Survival in Scleroderma Renal Crisis.
Binois Y, Buob D, Meuleman MS, Boudhabhay I, Isnard P, Rabant M, Gnemmi V, Daniel L, Brocheriou I, Gosset C, Frimat M, Quémeneur T, Mesbah R, Jourde-Chiche N, Moranne O, Housset P, Esteve E, Mathian A, Rivière S, Hummel A, Mouthon L, Chaigne B, Langlois AL, Thervet E, Aubert O, Roumenina L, Chauvet S, Karras A, Duong-Van-Huyen JP. Binois Y, et al. J Am Soc Nephrol. 2025 Nov 1;36(11):2201-2212. doi: 10.1681/ASN.0000000720. Epub 2025 May 7. J Am Soc Nephrol. 2025. PMID: 40333024
Cox model was performed to estimate the hazard ratios associated with histologic parameters for kidney failure, defined as the need for long-term dialysis therapy or eGFR <15 ml/min per 1.73 m(2) at the last follow-up. Multiplexed sequential immunofluorescence and proxi …
Cox model was performed to estimate the hazard ratios associated with histologic parameters for kidney failure, defined as the need for long …
68 results